122 related articles for article (PubMed ID: 2754707)
1. 9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as potential Alzheimer's disease therapeutics.
Shutske GM; Pierrat FA; Kapples KJ; Cornfeldt ML; Szewczak MR; Huger FP; Bores GM; Haroutunian V; Davis KL
J Med Chem; 1989 Aug; 32(8):1805-13. PubMed ID: 2754707
[TBL] [Abstract][Full Text] [Related]
2. (+/-)-9-Amino-1,2,3,4-tetrahydroacridin-1-ol. A potential Alzheimer's disease therapeutic of low toxicity.
Shutske GM; Pierrat FA; Cornfeldt ML; Szewczak MR; Huger FP; Bores GM; Haroutunian V; Davis KL
J Med Chem; 1988 Jul; 31(7):1278-9. PubMed ID: 3385720
[No Abstract] [Full Text] [Related]
3. Potential neurotoxicity of a novel aminoacridine analogue.
Walker TM; Starr B; Dewhurst BB; Atterwill C
Hum Exp Toxicol; 1995 Jun; 14(6):469-74. PubMed ID: 8519521
[TBL] [Abstract][Full Text] [Related]
4. Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats--Is there a potential for Alzheimer's disease treatment?
Misik J; Korabecny J; Nepovimova E; Kracmarova A; Kassa J
Neurosci Lett; 2016 Jan; 612():261-268. PubMed ID: 26708634
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and in vitro evaluation of 7-methoxy-N-(pent-4-enyl)-1,2,3,4-tetrahydroacridin-9-amine-new tacrine derivate with cholinergic properties.
Korabecny J; Musilek K; Zemek F; Horova A; Holas O; Nepovimova E; Opletalova V; Hroudova J; Fisar Z; Jung YS; Kuca K
Bioorg Med Chem Lett; 2011 Nov; 21(21):6563-6. PubMed ID: 21920739
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological activity and safety profile of P10358, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease.
Smith CP; Bores GM; Petko W; Li M; Selk DE; Rush DK; Camacho F; Winslow JT; Fishkin R; Cunningham DM; Brooks KM; Roehr J; Hartman HB; Davis L; Vargas HM
J Pharmacol Exp Ther; 1997 Feb; 280(2):710-20. PubMed ID: 9023283
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.
Fang L; Appenroth D; Decker M; Kiehntopf M; Roegler C; Deufel T; Fleck C; Peng S; Zhang Y; Lehmann J
J Med Chem; 2008 Feb; 51(4):713-6. PubMed ID: 18232655
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and in vitro evaluation of N-(Bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer's disease treatment.
Korabecny J; Musilek K; Holas O; Nepovimova E; Jun D; Zemek F; Opletalova V; Patocka J; Dohnal V; Nachon F; Hroudova J; Fisar Z; Kuca K
Molecules; 2010 Dec; 15(12):8804-12. PubMed ID: 21127466
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease.
Camps P; El Achab R; Görbig DM; Morral J; Muñoz-Torrero D; Badia A; Eladi Baños J; Vivas NM; Barril X; Orozco M; Luque FJ
J Med Chem; 1999 Aug; 42(17):3227-42. PubMed ID: 10464010
[TBL] [Abstract][Full Text] [Related]
10. Novel tacrine analogs as potential cholinesterase inhibitors in Alzheimer's disease.
El-Malah A; Gedawy EM; Kassab AE; Salam RM
Arch Pharm (Weinheim); 2014 Feb; 347(2):96-103. PubMed ID: 24343873
[TBL] [Abstract][Full Text] [Related]
11. New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β-amyloid-reducing properties.
Fernández-Bachiller MI; Pérez C; Monjas L; Rademann J; Rodríguez-Franco MI
J Med Chem; 2012 Feb; 55(3):1303-17. PubMed ID: 22243648
[TBL] [Abstract][Full Text] [Related]
12. Substituted Aminobenzothiazole Derivatives of Tacrine: Synthesis and Study on Learning and Memory Impairment in Scopolamine-Induced Model of Amnesia in Rat.
Ahmadi A; Roghani M; Noori S; Nahri-Niknafs B
Mini Rev Med Chem; 2019; 19(1):72-78. PubMed ID: 30009706
[TBL] [Abstract][Full Text] [Related]
13. Novel tacrine-1,2,3-triazole hybrids: In vitro, in vivo biological evaluation and docking study of cholinesterase inhibitors.
Najafi Z; Mahdavi M; Saeedi M; Karimpour-Razkenari E; Asatouri R; Vafadarnejad F; Moghadam FH; Khanavi M; Sharifzadeh M; Akbarzadeh T
Eur J Med Chem; 2017 Jan; 125():1200-1212. PubMed ID: 27863370
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and evaluation of novel tacrine-rhein hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Li SY; Jiang N; Xie SS; Wang KD; Wang XB; Kong LY
Org Biomol Chem; 2014 Feb; 12(5):801-14. PubMed ID: 24310227
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.
Muñoz-Ruiz P; Rubio L; García-Palomero E; Dorronsoro I; del Monte-Millán M; Valenzuela R; Usán P; de Austria C; Bartolini M; Andrisano V; Bidon-Chanal A; Orozco M; Luque FJ; Medina M; Martínez A
J Med Chem; 2005 Nov; 48(23):7223-33. PubMed ID: 16279781
[TBL] [Abstract][Full Text] [Related]
16. Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes.
Nielsen JA; Mena EE; Williams IH; Nocerini MR; Liston D
Eur J Pharmacol; 1989 Nov; 173(1):53-64. PubMed ID: 2606156
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of 5-amino-5,6,7,8-tetrahydroquinolinones as potential agents for the treatment of Alzheimer's disease.
Fink DM; Bores GM; Effland RC; Huger FP; Kurys BE; Rush DK; Selk DE
J Med Chem; 1995 Sep; 38(18):3645-51. PubMed ID: 7658452
[TBL] [Abstract][Full Text] [Related]
18. Velnacrine thiaanalogues as potential agents for treating Alzheimer's disease.
Tabarrini O; Cecchetti V; Temperini A; Filipponi E; Lamperti MG; Fravolini A
Bioorg Med Chem; 2001 Nov; 9(11):2921-8. PubMed ID: 11597473
[TBL] [Abstract][Full Text] [Related]
19. Toxicological and pharmacological evaluation, antioxidant, ADMET and molecular modeling of selected racemic chromenotacrines {11-amino-12-aryl-8,9,10,12-tetrahydro-7H-chromeno[2,3-b]quinolin-3-ols} for the potential prevention and treatment of Alzheimer's disease.
Oset-Gasque MJ; González MP; Pérez-Peña J; García-Font N; Romero A; del Pino J; Ramos E; Hadjipavlou-Litina D; Soriano E; Chioua M; Samadi A; Raghuvanshi DS; Singh KN; Marco-Contelles J
Eur J Med Chem; 2014 Mar; 74():491-501. PubMed ID: 24502897
[TBL] [Abstract][Full Text] [Related]
20. Cholinesterase inhibition in the scopolamine model of dementia.
Wesnes KA; Simpson PM; White L; Pinker S; Jertz G; Murphy M; Siegfried K
Ann N Y Acad Sci; 1991; 640():268-71. PubMed ID: 1776749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
